

Helix BioMedix Announces New Board Member: Barry L. Seidman

Nov 17, 2004 - Bothell, Washington

Helix BioMedix ([HXBM.OB](#)), an early stage biotechnology company, announced today that Barry L. Seidman has joined the Company's Board of Directors.

Barry Seidman has been Chairman of the Board of Pax Holding Corporation since 2001 and, for the preceding ten years, Mr. Seidman was an independent consultant within the securities industry.

In prior years, Mr. Seidman was President and Chief Operating Officer of First Options of Chicago and a Partner of Spear Leeds and Kellogg. He also served in various positions at The Options Clearing Corporation, culminating as First Vice President of National Operations. In the past he has served on the Board of Governors of the Philadelphia Stock Exchange and on the Board of Directors of The Options Clearing Corporation. He has also served on numerous securities industry committees over the past 25 years. Barry is a graduate of St. John's University with a B.S. in accounting.

R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix stated, "We are delighted that Mr. Seidman has agreed to join our Board of Directors. Barry augments the Helix BioMedix Board with over 30 years of experience dealing with a wide range of complex strategic planning and financing issues."

About Helix BioMedix:

Helix BioMedix, Inc. is an early-stage biotechnology company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at www.helixbiomedix.com.